Skip to main content
. 2020 Jul 10;8:540. doi: 10.3389/fcell.2020.00540

FIGURE 4.

FIGURE 4

MiR-138 treatment results in decreased expression of PD-L1 in tumor cells. (A) The gene expression levels of PD-L1 in tumors from lent-miR-138 (lent-M) treated mice were lower than those of the lent-NC (lent-N) treatment and untreated groups. (B) PD-L1 protein expression levels in tumors from microRNA-138 treated mice were lower than those of the NC treatment and untreated groups. (C) Flow cytometry analyzed showed that the level of PD-L1 expression on the CD133 + tumor cells from lent-M treated mice was lower than those of the lent-N treatment and untreated groups. (D) Immunofluorescence showed that the level of PD-L1 expression on tumors from lent-M treated mice was lower than those with lent-N treatment and untreated groups. Bar = 100 μm (**P < 0.01). (E,F) After miR-138 treatment, the gene and protein levels of PD-L1 were decreased in A549 cells. A549 cells were transfected with miR-138 mimic lentivirus (lent-M) or the corresponding negative control (lent-N). Twenty-four hours after lentiviral transfection, RT-qPCR (E) or Western-blot (F) was performed to examine the gene expression levels of miR-138 in A549 cells (***P < 0.001). (G) Flow cytometry analyzed showed that the expression of PD-L1 on the surface of untreated A549 cells, and A549 cells treated with lent-M and lent-N, respectively (***P < 0.001). (H) The expression of PD-L1 and PD-1 on the surface of tumor infiltrating DCs from lent-M, lent-N treated A549 bearing mice or not (mock), respectively (***P < 0.001).